BioInvent International AB (LTS:0H22) FCF Margin % : -464.03% (As of Dec. 2024)

View and export this data going back to . Start your Free Trial

What is BioInvent International AB FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. BioInvent International AB's Free Cash Flow for the three months ended in Dec. 2024 was kr-99.16 Mil. BioInvent International AB's Revenue for the three months ended in Dec. 2024 was kr21.37 Mil. Therefore, BioInvent International AB's FCF Margin % for the quarter that ended in Dec. 2024 was -464.03%.

As of today, BioInvent International AB's current FCF Yield % is -20.40%.

The historical rank and industry rank for BioInvent International AB's FCF Margin % or its related term are showing as below:

LTS:0H22' s FCF Margin % Range Over the Past 10 Years
Min: -1336.68 Med: -290.98 Max: -16.44
Current: -873.88

During the past 13 years, the highest FCF Margin % of BioInvent International AB was -16.44%. The lowest was -1336.68%. And the median was -290.98%.

LTS:0H22's FCF Margin % is ranked worse than
77.28% of 999 companies
in the Biotechnology industry
Industry Median: -121.51 vs LTS:0H22: -873.88

BioInvent International AB FCF Margin % Historical Data

The historical data trend for BioInvent International AB's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioInvent International AB FCF Margin % Chart

BioInvent International AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

-47.04

-1,336.68

-16.44

-507.71

-892.80

BioInvent International AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-490.53	-1,147.51	-2,692.08	-775.83	-464.03

Competitive Comparison of BioInvent International AB's FCF Margin %

For the Biotechnology subindustry, BioInvent International AB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioInvent International AB's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioInvent International AB's FCF Margin % distribution charts can be found below:

* The bar in red indicates where BioInvent International AB's FCF Margin % falls into.

Save Embed

;

Save Embed

;

BioInvent International AB FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

BioInvent International AB's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-398.958	/	44.686
	=	-892.80 %

BioInvent International AB's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-99.159	/	21.369
	=	-464.03 %

BioInvent International AB FCF Margin % Related Terms

Thank you for viewing the detailed overview of BioInvent International AB's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

BioInvent International AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioInvent International AB (LTS:0H22) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

BINV:Sweden BIX0:Germany

Address

Ideongatan 1, Lund, SWE, SE-223 70

Website

https://www.bioinvent.com

BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.

BioInvent International AB Headlines

No Headlines